- Home
- NAGE vs CGEN Comparison
NAGE vs CGEN Comparison
Compare NAGE & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAGE | CGEN |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.8M | 201.8M |
| IPO Year | 2010 | 2001 |
Fundamental Metrics
Financial Performance| Metric | NAGE | CGEN |
|---|---|---|
| Price | $2.07 | $2.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $10.67 | $4.80 |
| AVG Volume (30 Days) | ★ 518.4K | 229.9K |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.82 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $129,423,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.79 | $55.33 |
| P/E Ratio | $30.50 | ★ N/A |
| Revenue Growth | ★ 29.95 | N/A |
| 52 Week Low | $2.04 | $1.43 |
| 52 Week High | $7.12 | $3.24 |
Technical Indicators
Market Signals| Indicator | NAGE | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 35.09 | 49.52 |
| Support Level | $2.04 | $1.98 |
| Resistance Level | $3.61 | $2.33 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 5.41 | 73.68 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.